6:37 am Petrobras Brasileiro announced the concluded negotiations on various loan contracts (PBR) : The loan contracts include:

• R$ 4.5 billion export note with Banco do Brasil through its subsidiary BR Distribuidora for a 6-year period. 
• R$ 2 billion standby loan with Caixa Econmica Federal for a 5-year period. 
• R$ 3 billion standby loan with Bradesco for a 5-year period. Cooperation Agreement with Standard Chartered Bank for the sale and leaseback of production platforms totaling up to $3 billion and for a 10-year period.
• These transactions, along with the ones already entered into this year, will meet the company's 2015 financing requirements
  

6:36 am Intrawest Resorts preannounces Q3 results; reaffirms FY15 guidance (SNOW) : Co is initiating a process to re-price its Term Loan under the Company's existing Credit Agreement. In conjunction with that process, the Company announced the following preliminary results for Q3:

• The Company estimates net income attributable to Intrawest Resorts Holdings, Inc. will be between $126.0 million and $129.0 million. 
• Adjusted EBITDA is estimated to be between $154.0-157.0 mln v. ests near $149 mln. 
• Total reportable segment revenue is estimated to be between $317.0 million and $323.0 million. 
• Season pass and frequency product sales have grown 17.0% through April 9, 2015, relative to the same time last year. 
• The Company reiterates Fiscal 2015 Guidance.
  

6:33 am Hasbro beats by $0.13, beats on revs (HAS) : Reports Q1 (Mar) earnings of $0.21 per share, $0.13 better than the Capital IQ Consensus Estimate of $0.08; revenues rose 5.0% year/year to $713.5 mln vs the $660.27 mln consensus. Excluding a negative $62.6 million impact from foreign exchange, revenues increased 14%.

• "2015 is off to a good start with continued momentum in our business, led by growth in all of our Franchise Brands and the underlying strength in demand across international markets, including the emerging markets."
  

6:32 am Oncolytics Biotech announces that a series of poster presentations by its research collaborators will be made at the 2015 AACR Annual Meeting (ONCY) : The first abstract/poster titled "Combination therapy of reovirus and PD-1 blockade effectively established tumor control via innate and adaptive immune responses," was authored by Melcher, et al. The authors concluded that in an immune-competent murine melanoma model the combination therapy of reovirus with PD-1 blockade confers significant survival benefit, by augmenting tumor-specific natural killer (NK.V) responses and specifically attenuating tumor-specific immunosuppression. These data also suggest that combination of PD-1 inhibition therapy with reovirus oncolytic/immunotherapy represents a readily translatable method to enhance the therapeutic efficacy.

• The second abstract/poster titled "Oncolytic virus (RT3D) administration in combination with cetuximab in head and neck squamous cell cancer (:HNSCC) models harboring active EGFR/RAS/P13K signaling," was authored by Psyrri, et al. The authors concluded that in a transgenic mouse to test the therapeutic effect of combination of cetuximab treatment and RT3D infection in a mouse model of ras-driven oral SCC, RT3D infection exhibits a strong oncolytic effect in cetuximab resistant HNSCC with activated EGFR/RAS/MAPK signaling. The findings provided evidence that RAS independent molecular mechanisms can also support the RT3D proliferation in this subset of HNSCC.
• The third abstract/poster titled "Synergistic mechanisms of oncolytic reovirus with bortezomib in overcoming therapy resistance of multiple myeloma," was authored by Morris et al. Using a number of multiple myeloma cell lines the authors concluded that not all multiple myeloma cell lines are amenable to reovrius mediated cell death and that this has important implications for the future use of reovirus as a therapeutic agent.
• The fourth abstract/poster titled "Oncolytic viral therapy with immune modulation is an effective novel treatment strategy for non-small cell lung cancer (:NSCLC)," was also authored by Morris et al.
  

6:30 am BioTime subsidiary OncoCyte Corporation announces positive clinical results of its PanC-Dx Diagnostic Test; test demonstrated a high level of sensitivity and specificity in non-invasive detection of bladder cancer (BTX) : The first clinical study was conducted by OncoCyte in collaboration with investigators in the Department of Pathology at Johns Hopkins University School of Medicine. Clinical investigation involved collection of 90 urine samples from patients undergoing urine cytology for the diagnosis of either primary or recurrent bladder cancer. Study investigators then investigated the performance the 43-marker panel derived from the first clinical study using a set of 195 urine samples obtained from a second, large ongoing clinical study at multiple urology clinics in the United States. Performance of the classifier was evaluated using several cross-validation criteria, including Receiver Operating Characteristic area under the curve analysis, yielding an AUC of 0.91. Optimal performance of the classifier was achieved using only two markers.

6:21 am Genworth Financial responds to the final Private Mortgage Insurer Eligibility Requirements (GNW) : The co noted that based on its interpretation of the final PMIERs, the company still estimates $500 to $700 million of additional capital will be required to be fully compliant by the effective date. This estimate is based on a number of factors including the company's view of market size and dynamics, planned internal restructuring within U.S. Mortgage Insurance (U.S. MI) and current affiliate asset valuation. The estimate does not reflect today's announcement of changes to GSE fees (loan level pricing adjustments and adverse market fees), the impact of which the company is still evaluating. The final PMIERs lowered the level of required capital from that contained in the draft requirements, primarily benefiting legacy books of business, and also lowering the benefit from captive reinsurance treaties. Additionally, this estimate reflects reductions in affiliate asset valuation due to changes in market value, currency fluctuations and the finalization of the PMIERs.

•  The company still intends to comply with the final PMIERs by the effective date, which is now December 31, 2015.
  

6:16 am Pandora A/S announces that it will launch an e-commerce platform in the US (PNDZY) : The launch is part of the Company's aim to offer it jewelry online globally, and with the introduction of a PANDORA owned E-store in the US, co now offers E-stores in 8 countries. The E-store will, as is the case with the European E-stores, be operated by PFSWeb

6:15 am PG&E confirmed gas line rupture over the weekend (PCG) : Co announces Workers not affiliated with PG&E apparently struck a 12-inch natural gas transmission pipeline this afternoon in Fresno; no call had been placed to 811. The gas that was released by the dig-in ignited, and there were reports of injuries.

PG&E responded quickly after the pipeline was struck. PG&E detected a slight change in pressure at 2:29 p.m., and was first notified about the incident at 2:36 p.m. Actions to shut off gas began before 3 p.m., and the flow of gas to the pipeline was shut at 3:20 p.m. Because of the remaining gas in the line, the flames were exhausted at 3:56 p.m.

6:13 am GDF Suez announces a natural gas discovery in the Illizi Basin, in Southeast Algeria (GDFZY) : The TESO-2 well was drilled to a depth of 1,307 meters in the Ordovician reservoir. A successful test produced a gas flow of 175,000 cubic meters per day.TESO-2 is the first well of the second exploration program carried out under this licence, which started in January 2015. The drilling program includes at least four additional appraisal wells. GDF SUEZ holds 20% of the Sud-Est Illizi licence alongside the operator Repsol (52.5%) and Enel Spa (27.5 %). SONATRACH will participate with a 51% stake in the development and production phases.

6:06 am Kamada Reports announces additional data from its European Phase 2/3 clinical study of inhaled Alpha-1 Antitrypsin, demonstrating efficacy in a variety of lung function measurements (KMDA) : announces additional results from its European Phase 2/3 clinical trial of the Company's inhaled alpha-1 antitrypsin to treat AAT deficiency. Kamada performed these post hoc analyses in accordance with guidance received following the Company's meeting with European Medicines Agency Rapporteurs in December 2014.

• For lung function, overall one year effect: 
• FEV1 (L) rose significantly in AAT treated patients and decreased in placebo treated patients 
• There was a trend towards better FEV1% predicted
• FEV1/SVC% rose significantly in AAT treated patients and decreased in placebo treated patients 
• For lung function change at week 50 vs. baseline: 
• There was a trend towards reduced FEV1 decline 
• There was a trend towards a reduced decline in FEV1% predicted
• FEV1/SVC% rose significantly in AAT treated patients and decreased in placebo treated patients

6:05 am On The Wires (:WIRES) :

• Teradata (TDC) announced the launch of the Software-Defined Warehouse, an enhancement to the Teradata Database. The Software-Defined Warehouse enables organizations to consolidate multiple data warehouses into one system without sacrificing security or service level performance. 
• Ericsson (ERIC) and Intel (INTC) Security are working together to make managed security solutions available for telecom operators to bundle with the existing services they provide to enterprises. 
• TowerJazz (TSEM) and Gpixel announced the world's first backside illuminated (BSI) scientific CMOS image sensor, Gpixel's GSENSE400-BSI, manufactured using TowerJazz's TS18IS process. 
• Radware (RDWR) released a new and fully-managed, cloud-based Web Application Firewall (WAF.V) service that provides unmatched protection from web-based cyber-attacks.
  

6:03 am SunTrust Banks beats by $0.06, reports revs in-line (STI) : Reports Q1 (Mar) adj earnings of $0.78 per share, $0.06 better than the Capital IQ Consensus Estimate of $0.72; revenues fell 1.9% year/year to $1.99 bln vs the $2.01 bln consensus. 

• Mortgage production-related income for the current quarter was $83 million compared to $61 million for the prior quarter and $43 million for the first quarter of 2014. 
• Co rerpoted Q1 NIM of 2.83% vs 2.96% in Q4.
  

6:02 am Ascent Solar announces a stock purchase agreement with its existing stockholder TFG Radiant Investment Group for $1 mln in common stock (ASTI) : The transaction was priced at a fixed per share price of $1.00 and the Company has issued 1,000,000 restricted shares to TFG Radiant. The shares will become unrestricted one year from the closing date. 

6:01 am Hooper Holmes acquires accountable health solutions for $7 mln; expected to be accretive to Hooper Holmes' earnings in 2015 (HH) : The co announced it has acquired the assets representing the health and wellness business of Accountable Health Solutions, Inc. Accountable Health Solutions' unaudited financial statements reflect approximately $15 million in net sales during calendar year 2014. The purchase price was $7.0 million comprising $4 million cash and approximately $3 million in unregistered common stock, subject to a working capital adjustment. The acquisition is expected to be accretive to Hooper Holmes' earnings in 2015.

6:00 am Provectus Pharma and Pfizer (PFE) announce receipt of Patent Allowance for Use of PV-10 for the treatment of cancer (PVCT) : Cos announced that they have received from the US Patent and Trademark Office a Notice of Allowance for a joint patent application The patent will protect use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver. The allowed claims cover use of PV-10 in combination with systemic inhibitors of immune system down-regulation, such as anti-CTLA-4, PD-1 and PD-L1 antibodies, along with enhancers of immune system up-regulation, such as IL-2 and interferon-gamma.

6:00 am Sky-mobi announces appointment of Xiaodong Chen as CFO, effective April 20, 2015 (MOBI) : Prior to joining Sky-mobi, Mr. Chen served as the chief financial officer of ET Solar Group Corp, a provider of smart energy solutions, responsible for the company's equity financing, merger and acquisitions financial reporting and business restructuring from 2008 to 2015.

6:00 am MiX Telematics issues further cautionary announcement (MIXT) : The co notes that shareholders are referred to the cautionary announcement released on SENS on 5 March 2015 and are advised that MiX Telematics continues to investigate strategic alternatives relating to the company. Accordingly, shareholders are advised to continue exercising caution when dealing in the company's securities until a full announcement is made.

5:54 am European Markets : FTSE...7038.50...+43.90...+0.60%.  DAX...11819.56...+130.90...+1.10%.

5:54 am Asian Markets : Nikkei...19634.49...-18.40...-0.10%.  Hang Seng...27094.93...-558.20...-2.00%.

5:53 am S&P futures vs fair value: +13.00. Nasdaq futures vs fair value: +23.50. :

5:51 am America Movil SA shareholders approve spin-off (AMX) : The co announced that its shareholders, approved with a favorable vote of 98.2% the spin-off through which AMX will contribute to a sociedad annima burstil de capital variable called Telesites, S.A.B. de C.V., certain assets (mainly comprised of the passive infrastructure used by its wireless operations in Mexico), liabilities and equity. Additionally, it has been approved to initiate the necessary and convenient processes to implement the spin-off approved.

5:33 am Genetic Technologies announces additional breast health centres to begin offering BREVAGenplus (GENE) : Co announced that a further two new breast health centres will begin to offer BREVAGenplus to their at-risk patients in a systematic fashion. This is in addition to the six breast health centres that the Company previously announced were set to adopt BREVAGenplus, of which all six have in fact provided samples during the March 2015 quarter.

• With an additional number of new breast health centres expected to follow suit later in calendar year 2015, the Company reiterates that it expects sales growth to accelerate in the second half of calendar 2015 and beyond. 
• Importantly, the Company believes that the adoption of BREVAGenplus by a total of eight new breast health centres validates the company's recently re-focused sales and marketing strategy, announced in September 2014, whereby the Company shifted its focus to these large facilities. 
• While these centres are more complex entities with longer sales cycles, they offer higher and more stable long-term revenue potential. 

5:25 am Check Point Software beats by $0.04, reports revs in-line (CHKP) : Reports Q1 (Mar) earnings of $0.95 per share, $0.04 better than the Capital IQ Consensus Estimate of $0.91; revenues rose 9.0% year/year to $373 mln vs the $369.99 mln consensus.

• Share Repurchase Program: During the first quarter of 2015, the company repurchased 3.0 million shares at a total cost of $242 million, bringing the total share repurchase program to over $4 billion.
  

4:01 am On The Wires (:WIRES) :

• Toshiba Corporation (TOSBF) announced the start of demonstration operation of H2One, an independent energy supply system based on renewable energy and use of hydrogen as a fuel for power generation. Kawasaki City and Toshiba have installed the system at the Kawasaki Marien public facility and Higashi-Ogishima-Naka Park in the Kawasaki Port area. 
• SunPower (SPWR) announced that it has begun construction on the 86-megawatt peak Prieska solar power plant in South Africa's Northern Cape province. Expected to be fully operational in 2016 
• KeepItSafe, a premium, white-glove service for online disaster recovery and data backup, and a brand of j2 Global (JCOM), announced that the company has been awarded a G-Cloud Framework Agreement from the UK Government.

3:42 am Yara ASA writes down Lifeco investment by $112 mln (YARIY) : Co announces that due to the worsening security outlook in Libya, Yara sees a high likelihood of a further deterioration in 2015 of the operating ability of the Lifeco joint venture plants. Given an already challenging feedstock and financial situation for the joint venture, Yara has therefore decided to write down the value of its Lifeco investment by $112 million, leaving a remaining book value of $18 million.

• The political and security situation in Libya has worsened rapidly, and may deteriorate further over the next year. 
• In light of this, Yara is evaluating the operation of the plants on an on-going basis in cooperation with the other partners, in order to protect the employees as well as the assets.
  

3:37 am Pluristem Therapeutics' Clinical Advisory Board prepares Phase II clinical trials in critical limb ischemia in Europe and Japan (PSTI) : Co announced that its Clinical Advisory Board for Critical Limb Ischemia concluded a key meeting in London, England. During the meeting, Clinical Advisory Board members, including Key Opinion Leaders in the treatment of CLI, outlined the Phase II study design and other critical components of advanced-stage trials for the Company's PLacental eXpanded cells in the treatment of this peripheral artery disease.

• Pluristem has applied to conduct Phase II trials for CLI in regions with recently established rapid regulatory pathways, including the Accelerated Pathway for Regenerative Therapy in Japan and the Adaptive Pathway in the European Union.
  

3:22 am On The Wires (:WIRES) :

• Global Sources' (GSOL) 2015 spring electronics show second phase opens today with more than 1,900 booths focusing on mobile electronics. Held today through April 21 at AsiaWorld-Expo in Hong Kong, products categories covered include smartphones, tablets, drones, wearables and accessories. 
• PSA Peugeot Citron (PEUGY.PK) and Dongfeng Group announced a project to jointly develop a global platform for the manufacture of B and C segment vehicles under the Peugeot, Citron, DS and Dongfeng brands and to create a joint R&D centre based in Shanghai that will be dedicated to developing products and technologies for fast- growing Asian markets. The project calls for capital expenditure of 200 million, of which 60% will be committed by PSA and 40% by DFG.

3:17 am Prologis reports FFO in-line, beats on revs; guides FY15 FFO in-line (PLD) : Reports Q1 (Mar) funds from operations of $0.49 per share, in-line with the Capital IQ Consensus Estimate of $0.49; revenues rose 6.5% year/year to $462.9 mln vs the $413.63 mln consensus. Co issues in-line guidance for FY15, sees FFO of $2.07-2.13 vs. $2.08 Capital IQ Consensus Estimate.
Additional guidance

• Year-end occupancy between 95.5 and 96.5 percent 
• GAAP same store NOI growth between 3.75 and 4.50 percent 
• Development stabilizations between $1.7 and $1.9 billion 
• Development starts between $2.3 and $2.6 billion 
• Building acquisitions between $1.0 and $1.5 billion 
• Contributions to co-investment ventures between $1.3 and $1.8 billion
  
  

3:06 am Prologis signs definitive agreements to acquire $5.9 bln portfolio from KTR Capital Partners; expected to be accretive to Core FFO by $0.14 (PLD) : Prologis, Inc. (NYSE: PLD), the global leader in industrial real estate, today announced it has signed definitive agreements to acquire the real estate assets and operating platform of KTR Capital Partners and its affiliates for a total purchase price of $5.9 billion. The properties comprise KTR's three co-investment funds and will be acquired by Prologis U.S. Logistics Venture, a 55-45 consolidated joint venture with Norges Bank Investment Management, manager of the Norwegian Government Pension Fund Global.

Transaction / Structure
The total consideration for the transaction is $5.9 billion, including the assumption of approximately $700 million of secured mortgage debt and the issuance of up to $230 million (less assumed liabilities) of common limited partnership units in Prologis to KTR.

Accretion / Cost Savings / Currency Benefits

• The transaction is expected to be accretive to forecasted annual core funds from operations (Core FFO) by ~$0.14 per share, on a stabilized basis. This represents 7% growth from the midpoint of Prologis' 2015 guidance. 
• Contemporaneously, Prologis has obtained a commitment from Morgan Stanley Senior Funding to provide a $1.0 billion bridge facility for the transaction, which provides ample capacity while maintaining significant liquidity on its credit facilities. 
• Additionally, the transaction is expected to lower general and administrative expenses as a percentage of assets under management by ~12% and increase its U.S. dollar equity exposure to 93%

2:49 am Koninklijke Ahold repurchased 1,179,305 common shares in the period from April 13-17 (AHONY) : The shares were repurchased at an average price of 18.6041 per share for a total consideration of 21.94 million. These repurchases were made as part of the 500 million share buyback program announced on February 26, 2015. The total number of shares repurchased under this program to date is 3,310,249 common shares for a total consideration of 60.64 million.

2:30 am Liberty Global's subsidiary Telenet to acquire BASE (LBTYA) : Co announced that its subsidiary Telenet Group Holding NV has entered into a definitive agreement to acquire BASE Company NV from Royal KPN (KKPNY), the third-largest mobile network operator in Belgium in an all cash transaction valuing BASE Company at 1.325 billion.

• This represents a purchase price multiple of 4.2x BASE Company's estimated 2015 OCF1, as adjusted for approximately 145 million of projected annual run-rate opex synergies2. When the enterprise value is increased to include ~240 million of projected one-off investments and integration costs, the synergy adjusted multiple increases to 5.0x3. 
• This acquisition will enable Telenet to compete more effectively in a mobile market with significant growth opportunities, while offering a full range of fixed and mobile services to the benefit of consumers and businesses in Belgium.
  

2:20 am Air Products and ACWA Holding awarded contract by Saudi Aramco to build, own and operate the world's largest industrial gas complex (APD) : Air Products announced that it has been awarded a contract by Saudi Aramco under a joint venture of Air Products and ACWA Holding to build, own and operate the world's largest industrial gas complex to supply 75,000 metric tons per day (20,000 oxygen and 55,000 nitrogen) to Saudi Aramco's refinery being built in Jazan, Saudi Arabia for 20 years.

• The industrial gas complex will be designed and built by Air Products using its proprietary technology. 
• Once built, this facility will be owned by a JV of Air Products (25%) and ACWA Holding (75%). 
  

2:02 am DelMar Pharma presents positive preclinical data on VAL-083 for treatment of non-small cell lung cancer (DMPI) : Co announced positive preclinical data on its lead product candidate VAL-083 for treatment of platinum drug-resistant non-small cell lung cancer and as a potential combination therapy option in newly diagnosed NSCLC patients.

• DelMar's study demonstrated that VAL-083's mechanism is distinct from platinum-based chemotherapy, the current standard of care for NSCLC. VAL-083 retains its high level of anti-cancer activity in p53 mutated NSCLC cell lines compared to cisplatin or oxaliplatin which provides support for the potential of VAL-083 as a viable treatment option for NSCLC patients failing platinum-based therapy. 
• In addition, the combination of VAL-083 with either cisplatin or oxaliplatin demonstrated superadditivity/synergy against NSCLC cell lines, including those resistant to tyrosine kinase inhibitors. These results support the potential benefit of a VAL-083/platinum combination therapy in newly diagnosed NSCLC patients.
  
  

1:57 am Merck presents early findings with KEYTRUDA in patients with advanced pleural mesothelioma (MRK) : Co announced the first presentation of data investigating the use of KEYTRUDA, the company's anti-PD-1 therapy, in 25 patients with advanced pleural mesothelioma, a difficult-to-treat cancer of the lining of the lungs, abdomen and other organs.

• The early findings presented showed an overall response rate (confirmed and unconfirmed) of 28% with KEYTRUDA in patients with tumors that expressed PD-L1.
• Additionally, 48% of patients had stable disease, resulting in a disease control rate of 76%
  

1:46 am Merck announces submission of supplemental Biologics License Application to FDA for KEYTRUDA in advanced non-small cell lung cancer (MRK) : Co announced that it has submitted a supplemental Biologics License Application to the FDA for KEYTRUDA, the company's anti-PD-1 therapy, for the treatment of advanced non-small cell lung cancer.

• KEYTRUDA previously received Breakthrough Therapy designation for advanced NSCLC and this initial filing seeks approval in the treatment of patients with advanced NSCLC whose disease has progressed on or after platinum-containing chemotherapy and an FDA-approved therapy for EGFR or ALK genomic tumor aberrations, if present. 
• Under PDUFA, the FDA has 60 days from submission of the sBLA to determine if the application will be accepted for review. The submission is based on data from KEYNOTE-001 in patients with greater than or equal to 50 percent of tumor cells positive for PD-L1 expression.
  
• The efficacy findings demonstrated that tumor PD-L1 expression may be a relevant biomarker for the identification of NSCLC patients with an enhanced likelihood of experiencing improved efficacy with an anti-PD-1 therapy. 
• PD-L1 is a protein that may be overexpressed in the tumor and may contribute mechanistically to an inhibited immune response.
  

1:29 am NMI Hldgs comments on new private MI eligibility standards (NMIH) : Co commented on the final Private Mortgage Insurer Eligibility Requirements released today by the Federal Housing Finance Agency. The PMIERs establish more stringent standards for determining a mortgage insurance company's eligibility to insure loans sold to or guaranteed by Fannie Mae and Freddie Mac. The PMIERs will go into effect on December 31, 2015. Insurers will have a transition period to satisfy the financial requirements of PMIERs, but not beyond July 1, 2017.

• "National MI welcomes the new PMIERs...This initiative reinforces the importance of a sound and financially sustainable private mortgage insurance industry, which is a critical component of a healthy residential mortgage market. With significant undeployed capital, National MI is well positioned to continue to grow insurance-in-force and to take on an increasing role in providing credit enhancement to the housing finance industry, reducing the government's footprint."
  

1:25 am Exco Resources appoints Harold Jameson as Chief Operating Officer (XCO) : Co announced it has appointed Harold Jameson as EXCO's Chief Operating Officer, effective April 17, 2015.

• Jameson most recently served as EXCO's Vice President of Development & Production with primary responsibilities including EXCO's horizontal shale development drilling programs in the Haynesville, Eagle Ford and Marcellus assets. Mr. Jameson has served in a Vice President role since March 2011.
  

12:36 am Ignyta presents 3 posters at AACR highlighting developments relating to entrectinib (RXDX) : Co announced announced three poster presentations at the 106th Annual Meeting of the American Association for Cancer Research (:AACR) in Philadelphia, Pennsylvania.

Each of the presentations highlights developments relating to entrectinib (formerly known as RXDX-101), Ignyta's proprietary oral pan-Trk, ROS1 and ALK tyrosine kinase inhibitor targeting solid tumor indications. The first of the poster presentations describes the similarities and differences between Trk rearrangements and overexpression as potential oncogenic drivers and provides support for further exploration of entrectinib in cancers with Trk overexpression. The second presentation highlights a newly-developed biomarker assay to enable rapid screening of patient tumor samples to assess expression of TrkA, TrkB, TrkC and ROS1. The third poster presents data generated in collaboration with The Children's Hospital of Philadelphia and the University of Pennsylvania School of Medicine, showing that entrectinib treatment resulted in significant tumor growth inhibition in a neuroblastoma xenograft model, both alone and in combination with conventional chemotherapy, providing support for the potential clinical evaluation of entrectinib in neuroblastoma patients.